Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers
NCT02796131Phase 1Completed
- Sponsor
- Ardelyx
- Start
- Jul 2011
- Primary completion
- Oct 2011
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tenapanor in irritable bowel syndrome (IBS) and hyperphosphatemia (7 arms), sponsored by Ardelyx. Primary endpoint: Safety of different dosing regimens of RDX5791 at 7 days. Started Jul 2011; status: completed.
02
Drugs
tenapanor
03
Conditions
irritable bowel syndrome (IBS)hyperphosphatemia
Beyond the preview
Go deeper on NCT02796131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796131.